GluBio

Focus: GluBio is an early-stage biotechnology company headquartered in Shanghai specializing in targeted protein degradation (TPD) technology for oncology applications. The company is in very early clinical development with a pre-revenue, discovery-to-Phase 1 pipeline.

Oncology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Open Jobs

About GluBio

AI assessmentNot Hiring

No open roles listed right now. Follow GluBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GLB-001

Polycythemia Vera

Phase 1

Clinical Trials (1)

NCT06378437A Study of GLB-001 in Patients With Myeloid Malignancies

Phase 1

Help build intelligence for GluBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on cutting-edge targeted protein degradation platform, a high-growth modality attracting significant biotech interest
Ground-floor position at an early-stage company with potential for significant career growth and equity upside in the pre-clinical to clinical transition phase
Shanghai headquarters provides access to rapidly expanding Chinese biotech ecosystem and patient populations for oncology development

Watch Out For

Pre-revenue stage with unknown funding runway, employee count, and cash position creates significant financial stability risk
Only 1 active job opening and minimal hiring activity (1 R&D role) suggests very limited growth and career trajectory opportunities
All 3 pipeline programs remain in Phase 1 with no published clinical data, no near-term catalysts, and no clear path to Phase 2 advancement visibility

Generated by Claude from GluBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GLB-002

Non-Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT06219356A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Phase 1

GLB-001

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06146257A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Oncology, Hematology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Hematology

1 pipeline

Marketed

Pipeline